US Bancorp DE Has $35.23 Million Holdings in Solventum Corporation $SOLV

Key Points

• US Bancorp DE increased its stake in Solventum by 4.6% to 444,540 shares worth $35.23 million, purchasing an additional 19,400 shares and owning about 0.26% of the company.
• Solventum beat quarterly expectations with $1.57 EPS (vs. $1.50 est.) on $2.0 billion revenue, and set FY2026 guidance of 6.40–6.60 EPS (analysts expect ~6.5).
• The stock trades at a PE of 7.53 with a market cap of $11.58 billion; consensus rating is "Hold" with an average target of $89.45.

US Bancorp DE grew its holdings in Solventum Corporation (NYSE:SOLV - Free Report) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 444,540 shares of the company's stock after purchasing an additional 19,400 shares during the period. US Bancorp DE owned about 0.26% of Solventum worth $35,225,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOLV. Independent Franchise Partners LLP raised its holdings in shares of Solventum by 27.2% in the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company's stock valued at $941,645,000 after purchasing an additional 2,758,174 shares during the last quarter. Boston Partners raised its holdings in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company's stock valued at $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company's stock valued at $1,249,847,000 after purchasing an additional 867,837 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Solventum in the third quarter valued at approximately $42,393,000. Finally, Pzena Investment Management LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $31,701,000.

Solventum Price Performance

NYSE:SOLV opened at $66.78 on Friday. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The firm has a fifty day simple moving average of $67.99 and a 200 day simple moving average of $74.48. The stock has a market capitalization of $11.58 billion, a PE ratio of 7.53, a P/E/G ratio of 1.10 and a beta of 0.60.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion during the quarter, compared to analysts' expectations of $1.96 billion. During the same period last year, the business earned $1.41 earnings per share. The firm's revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, research analysts expect that Solventum Corporation will post 6.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of Solventum stock in a transaction on Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.24% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SOLV. Stifel Nicolaus lifted their price objective on shares of Solventum from $88.00 to $105.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Wells Fargo & Company raised shares of Solventum to a "hold" rating in a research note on Wednesday, March 18th. Mizuho set a $100.00 target price on shares of Solventum and gave the company an "outperform" rating in a research note on Tuesday, January 20th. KeyCorp decreased their target price on shares of Solventum from $99.00 to $92.00 and set an "overweight" rating for the company in a research note on Monday. Finally, Wall Street Zen cut shares of Solventum from a "buy" rating to a "hold" rating in a research note on Sunday, March 8th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $89.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.